

PRESS RELEASE

12/13 September 2018 : MOPEAD Consortium meets in Barcelona

Fundació ACE hosted the 4th MOPEAD Consortium meeting in their premises in Barcelona, on 12/13 September 2018. One of the main features of this meeting was to deliver on the recommendations issued in the project mid-term review in May 2018.

The first day was dedicated to the progression made regarding patient recruitment in the five clinical sites (Germany, Slovenia, Spain, Sweden and the Netherlands) and the four patient engagement strategies (Citizen Science, 'Open House', Primary Care Professional and Diabetologist settings). The participants shared their recruitment challenges and successes.

Overall, there are significant differences between the five clinical sites with Slovenia having made good progress with the Citizen Science and 'Open House' settings. The Citizen Science pre-screenings figures are rather low for Spain and Sweden, and have not started in Germany and the Netherlands. This is attributed to the fact that this recruitment strategy only started in July, during the holiday season and the delay in response from Ethic Review Committees. The delay is motivated by the innovative approach of the Citizen Science strategy. The 'Open House' setting shows a slow start in Sweden.

The discussion was an opportunity to brainstorm on the hurdles faced by some sites (Ethic Review Boards feed-back, holiday season, difficulty to engage PCPs and diabetologists, participants drop-out in the PCP and diabetologist settings when a diagnosis is proposed) and how to overcome them (advertising, support to PCPs and diabetologists, phone calls...).

The clinical sites partners were confident that the recruitment was now on track. However, it is highly possible that more than the scheduled 100 screenings will be needed to reach the figure of 33 participants receiving a diagnosis. It was agreed to extend the recruitment deadline to gather significant data that will allow a meaningful evaluation of the results.

The second day was dedicated to the exploitation of results (how to model the economic costs of each method and plans for the statistical modelling) and discussions on the technical aspects of the project (common protocol for evaluation progress overview and implementation of the diagnostic protocol). The project future Communication and Dissemination activities were presented. They include a video introducing the project. The innovative approach of the project and the challenges encountered by the clinical sites with the different patient engagement strategies will be made available to the scientific community via a series of articles.

Elisabetta Vaudano, IMI Principal Scientific Officer, took part in the meeting on-line and shared some recommendations.

The Consortium had invited Lutz Frölich, one of MOPEAD's external Advisors. Besides sharing precious comments about the project development, Lutz shared his views on the 'Problems and perspectives of clinical trials in MCI'. Lutz is Head of the Department for Geriatric Psychiatry at the Central Institute of Mental Health (ZI) Mannheim (Germany).



Why MOPEAD?

MOPEAD will contribute to the imperative to find interventions to halt AD. Dementia affects over 35 million people globally, a figure set to rise to over 115 million by 2050 due to the ageing of the population. AD puts a huge and growing burden on health and social systems, and the families and carers of those affected. Despite decades of research, there is still no treatment nor cure for the disease. It is therefore crucial to develop new interventions that will help identify hidden cases of AD. MOPEAD will do this through evaluating four patient engagement strategies and providing new insights for therapeutic interventions in clearly identified populations.

MOPEAD will respond to the urgency of finding interventions to halt AD by stimulating a faster recruitment of patients into clinical trials.

MOPEAD partners are Fundació ACE Institut Català de Neurociències Aplicades, Eli Lilly and Company Ltd, ASDM Consulting, AstraZeneca AB, European Institute of Women's Health, GMV Soluciones Globales Internet S.A.U., Karolinska Institutet, Modus Research and Innovation Ltd, Spomincica—Alzheimer Slovenia, University Hospital of Cologne, University Medical Centre Ljubljana, Fundacio Hospital Universitari Vall D'Hebron—Institut de Recerca, Stichting VUmc, Alzheimer Europe.

www.mopead.eu

@MopeadEU

Disclaimer

This communication reflects the author's view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

About Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need.

It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organizations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently needed new treatments in diverse areas.



IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

www.imi.europa.eu

For more information:

Ms. Annette Dumas – ASDM Consulting (general)



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115975. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and members of the European Federation of Pharmaceutical Industries and Associations

